Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 in mesalazine-refractory ulcerative colitis
NCT01011322Phase 2Unknown
- Sponsor
- Lipid Therapeutics GmbH
- Start
- Dec 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of phosphatidylcholine (LT-02) in ulcerative colitis (UC), sponsored by Lipid Therapeutics GmbH. Status: unknown.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01011322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011322.